Concentric Geographic Atrophy - 76 year old man441 x angesehenGradual vision loss, worse at night. VA 20/40 OU.30. Dezember 2019
Concentric Geographic Atrophy - 76 year old man429 x angesehenGradual vision loss, worse at night. VA 20/40 OU.30. Dezember 2019
Concentric Geographic Atrophy - 76 year old man415 x angesehenGradual vision loss, worse at night. VA 20/40 OU.30. Dezember 2019
Concentric Geographic Atrophy - 76 year old man411 x angesehenGradual vision loss, worse at night. VA 20/40 OU.30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane383 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane364 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane395 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane389 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane389 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane381 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane350 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane366 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane374 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane340 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane364 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane352 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane399 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane382 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane373 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane372 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane371 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane337 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane380 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane369 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane314 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane351 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane359 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane350 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane359 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane367 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane370 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane408 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane355 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane433 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane412 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane407 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane375 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane354 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane388 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane364 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane360 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Punctate Inner Choroidopathy and Choroidal Neovascular Membrane368 x angesehen27 year old female with vision loss for 4 months. VA was 20/200. She had a CNVM which was extrafoveal with no subretinal fluid. Her vision improved over 6 months to 20/50 with Ranibizumab injections (she might have improved without treatment)30. Dezember 2019
Angioid Streaks Scar and new CNVM392 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM432 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM357 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM379 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM370 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM376 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM363 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM429 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM356 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM369 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM364 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM349 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM363 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM377 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM397 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM398 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM373 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Angioid Streaks Scar and new CNVM400 x angesehen49 y/o WF with decreased vision x 1 month. Her OD is 20/400 and her OS is seeing 20/70. No cutaneous lesions or Ehlers-Danlos. The FP and FA show a predominant classic CNV (with fibrosis) OD and an Occult CNV OS with what appears to be a RAP lesion.21. Dezember 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM346 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM380 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM389 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM376 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM407 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM372 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM390 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM372 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM371 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM389 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM372 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM382 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM381 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM392 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM379 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM370 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM428 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM380 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM357 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM445 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM363 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM390 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM387 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM411 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM395 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM403 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM395 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM386 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM372 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM371 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM367 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM391 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM350 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM393 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM378 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM368 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM398 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM382 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM412 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
Rapid macular atrophy with anti-VEGF therapy for myopic CNVM384 x angesehen64 year old female with 20/32 vision and distortion in the left and better eye. She was treated with monthly lucentis and her vision declined to 20/100. Medicine was stopped and she improved a little to 20/80.17. November 2019
